TUXEDO-2 Trial Shows Noninferiority of Sirolimus-Eluting Stent vs Everolimus-Eluting Stent in Diabetic Patients

Join our community to access additional content!

CRT Community

$0.00

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Join Now!
Already have an account? Login Now

CRT Community Premium

$650.00 annually

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Complimentary subscription to electronic version of the CRM Journal

Access to CRT Meeting Registration Discounts

CRT Premium Content, including on-demand videos and presentation downloads

Join Now!
Already have an account? Login Now
News

TUXEDO-2 Trial Shows Noninferiority of Sirolimus-Eluting Stent vs Everolimus-Eluting Stent in Diabetic Patients

Posted: 07/01/2026
Author:
Bailey G. Salimes, CRTonline.org
News Articles 2026 Coronary Drug Eluting Stent (DES)Coronary Interventions News Percutaneous Coronary Intervention Stenting Coronary Artery Bypass Graft Clinical Cardiology

An ultra-thin biodegradable polymer (BP) sirolimus-eluting stent (SES) can be used as safely and effectively as a durable polymer (DP) everolimus-eluting stent (EES) in patients who have diabetes plus multivessel disease who undergo percutaneous coronary intervention (PCI), results from the TUXEDO-2 trial show.

Most Viewed Pages

DMV (July 2026) Feasibility and Challenges of the UNICORN Technique in Native Aortic Valve TAVI

Pericardiocentesis

Older, Symptomatic Patients With Mild Hypertrophic Cardiomyopathy More Likely to Develop MACE: SHaRe Registry

Pulsed Field Ablation for AF Shows Low Complication Rate, No Esophageal or Persistent Phrenic Injury: Registry Study

Optimizing Femoral Closure with ANGIO-SEAL® VIP Vascular Closure Device

Invalid Configuration Data. Please look into Pipeline and other configurations.

No record found for the searched term.

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Join our community to access additional content!

CRT Community

CRT Community Premium

News

TUXEDO-2 Trial Shows Noninferiority of Sirolimus-Eluting Stent vs Everolimus-Eluting Stent in Diabetic Patients

Most Viewed Pages

Explore the Site

Stay Connected